Everest Financial Group LLC Invests $1.26 Million in Merck & Co., Inc. $MRK

Key Points

• Everest Financial Group LLC disclosed a new first-quarter stake in Merck & Co., buying 10,475 shares valued at about $1.26 million.
• Merck announced initial access plans for its investigational once-monthly oral HIV PrEP, alimatravir, and said it has voluntary licensing agreements covering 129 countries, which could help expand global adoption if approved.
• Merck also faced a competitive setback as Par Health launched the first generic version of Janumet XR in the U.S., potentially pressuring sales of the diabetes drug.

Everest Financial Group LLC purchased a new stake in Merck & Co., Inc. (NYSE:MRK - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 10,475 shares of the company's stock, valued at approximately $1,260,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Merck & Co., Inc. by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 254,322,763 shares of the company's stock valued at $26,770,014,000 after purchasing an additional 2,185,853 shares in the last quarter. State Street Corp raised its holdings in shares of Merck & Co., Inc. by 1.6% in the fourth quarter. State Street Corp now owns 120,040,168 shares of the company's stock valued at $12,737,504,000 after acquiring an additional 1,859,990 shares in the last quarter. Wellington Management Group LLP lifted its stake in Merck & Co., Inc. by 14.8% in the fourth quarter. Wellington Management Group LLP now owns 86,435,458 shares of the company's stock worth $9,098,196,000 after acquiring an additional 11,156,354 shares during the period. Geode Capital Management LLC grew its holdings in Merck & Co., Inc. by 0.4% during the 4th quarter. Geode Capital Management LLC now owns 60,047,984 shares of the company's stock worth $6,307,572,000 after acquiring an additional 249,110 shares in the last quarter. Finally, Morgan Stanley grew its holdings in Merck & Co., Inc. by 0.8% during the 4th quarter. Morgan Stanley now owns 44,946,021 shares of the company's stock worth $4,731,018,000 after acquiring an additional 359,486 shares in the last quarter. Institutional investors own 76.07% of the company's stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck announced initial access plans for alimatravir, its investigational once-monthly oral HIV PrEP in Phase 3 development, and said it has signed voluntary licensing agreements covering 129 countries. That broad access strategy could support adoption in large international markets if the drug is approved. Article Title
• Neutral Sentiment: Merck also issued a company release on the same alimatravir access plan, reinforcing that the program is moving forward and that it is trying to expand availability in regions that account for most new HIV diagnoses globally. Article Title
• Neutral Sentiment: Traders also bought a high volume of Merck call options, which may reflect rising bullish speculation around the stock and the HIV pipeline, but it does not by itself change fundamentals. Article Title
• Negative Sentiment: Par Health launched the first generic version of Janumet XR in the U.S., which may pressure Merck’s diabetes-related sales and adds another competitive headwind for an established product. Article Title

Merck & Co., Inc. Trading Up 0.4%

NYSE:MRK opened at $131.06 on Friday. The stock has a market capitalization of $323.68 billion, a price-to-earnings ratio of 36.92, a PEG ratio of 5.20 and a beta of 0.19. Merck & Co., Inc. has a 52 week low of $76.66 and a 52 week high of $131.74. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The firm has a 50 day moving average of $121.67 and a 200 day moving average of $117.71.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.47) by $0.19. The business had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The business's revenue for the quarter was up 4.9% on a year-over-year basis. During the same period in the previous year, the company earned $2.22 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. As a group, sell-side analysts anticipate that Merck & Co., Inc. will post 2.74 earnings per share for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date was Monday, June 15th. Merck & Co., Inc.'s payout ratio is 95.77%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on MRK shares. Cantor Fitzgerald restated a "neutral" rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a report on Monday, July 6th. Guggenheim boosted their price objective on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a "buy" rating in a research note on Monday, July 13th. Wall Street Zen lowered Merck & Co., Inc. from a "buy" rating to a "hold" rating in a report on Monday, July 20th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $142.00 target price on shares of Merck & Co., Inc. in a research report on Wednesday, July 8th. Finally, BMO Capital Markets upped their price objective on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an "outperform" rating in a research note on Monday, July 13th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and seven have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $133.94.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.